Novartis AG (GB:0QLR)
LSE:0QLR
Want to see GB:0QLR full AI Analyst Report?
0QLR Stock Chart & Stats
CHF118.80
CHF0.25(0.27%)
At close: 4:00 PM EST
CHF118.80
CHF0.25(0.27%)
Day’s Range― - ―
52-Week RangeCHF87.99 - CHF131.02
Previous CloseN/A
Volume210.36K
Average Volume (3M)1.02M
Market Cap
CHF206.95B
Enterprise ValueCHF318.32B
Total Cash (Recent Filing)CHF7.00B
Total Debt (Recent Filing)CHF47.14B
Price to Earnings (P/E)23.4
Beta0.94
Next Earnings
Jul 21, 2026EPS Estimate
1.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.98
Shares Outstanding2,034,819,500
10 Day Avg. Volume801,914
30 Day Avg. Volume1,022,628
Financial Highlights & Ratios
PEG Ratio0.66
Price to Book (P/B)5.81
Price to Sales (P/S)4.69
P/FCF Ratio14.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF121.83Price Target Upside2.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)8.74
Revenue Forecast (FY)CHF56.83B
Bulls Say, Bears Say
Bulls Say
Acquisition Expands Late-stage PipelineAnalyst highlights that a bolt-on acquisition adds two late-stage drug candidates that could materially expand future revenue potential and reduce reliance on organic product cycles.
Prescription MomentumAnalyst notes strong prescription trends for multiple recently launched therapies that underpin revenue growth prospects and support expanding market uptake.
Promising Remibrutinib ProfileAnalyst views remibrutinib as a leading pipeline asset with a cleaner liver safety profile and differentiated properties that increase the drug's potential to gain market share across disease areas.
Bears Say
Biomarker And Regulatory UncertaintyAnalyst cautions that variability in key biomarkers and uncertainty over whether biomarker improvements translate into meaningful clinical benefit could complicate regulatory approval and commercial adoption.
Clinical And Safety Uncertainty For BTK ProgramAnalyst notes absence of intermediate-stage multiple sclerosis data and questions about brain penetration and potency, creating uncertainty around the BTK program's efficacy and competitive positioning.
Generic Competition And Margin PressureAnalyst warns that erosion from generic competition on several legacy medicines is weighing on sales and reducing operating margins, pressuring profitability metrics.
0QLR FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest share price was CHF87.99 and its highest was CHF131.02 in the past 12 months.
What is Novartis AG’s market cap?
Novartis AG’s market cap is CHF206.95B.
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Jul 21, 2026 which is in 70 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Apr 28, 2026. The company reported CHF1.549 earnings per share for the quarter, missing the consensus estimate of CHF1.638 by -CHF0.089.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Undervalued.
Does Novartis AG pay dividends?
Novartis AG does not currently pay dividends.
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is 1.7.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,034,819,500 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of CHF1.549 in its last earnings report, missing expectations of CHF1.638. Following the earnings report the stock price went down -1.056%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in GB:0QLR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
0QLR Stock 12 Month Forecast
Average Price Target
CHF121.83
▲(2.55% Upside)
Technical Analysis
Options Prices
Currently, No data available
---